1. Screening Libraries
  2. Histone Modification Research Compound Library

Histone Modification Research Compound Library

(669) Cat. No.: HY-L024
Library Contents: XLSX PDF

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 669 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Size (Pre-dissolved DMSO or Solid) Price Stock
30 μL/well (10 mM solution) Get quote In-stock
50 μL/well (10 mM solution) Get quote In-stock
100 μL/well (10 mM solution) Get quote In-stock
250 μL/well (10 mM solution) Get quote In-stock

Please contact us at

sales@MedChemExpress.com

Top Publications Citing Use of Products

Customer Validation

MCE Screening Library Partners

  • Description

  • Product Details

  • Composition

  • Contents

  • Documentation

Description
& Advantages

•   A unique collection of 669 bioactive compounds for high throughput screening (HTS) and high content screening (HCS).

•   Targets include Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc.

•   A useful tool for the research of the regulation of histone modification and the corresponding diseases.

•   Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.

•   Structurally diverse, medicinally active, and cell permeable.

•   More detailed compound information with structure, IC50, and brief introduction.

•   NMR and HPLC validated to ensure high purity and quality.

•   All compounds are in stock and continuously updated.

Product Details
Formulation:
A collection of 669 histone modification related compounds supplied as pre-dissolved Solutions or Solid
Container:
96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
Storage:
-80°C
Shipping:
Blue ice or dry ice
Composition

Contents of Histone Modification Research Compound Library

Plate layout: HY-L024-1

1 2 3 4 5 6 7 8 9 10 11 12
a Empty HLCL-61 (hydrochloride) EPZ015866 NKL 22 Vorinostat CUDC-101 Panobinostat Belinostat TG-101348 TG101209 Tasquinimod Empty
b Empty Valproic acid (sodium salt) BIX-01294 UNC0321 PCI-24781 KU-57788 Entinostat Mocetinostat MM-102 (trifluoroacetate) IOX1 UNC0379 Empty
c Empty OF-1 A-366 SP2509 ML324 GSK503 (+)-JQ-1 (R)-(-)-JQ1 Enantiomer GSK 525762A I-BET151 Droxinostat Empty
d Empty Tubastatin A (Hydrochloride) Tubastatin-A Pracinostat Tenovin-1 GSK126 M344 Sirtinol Dacinostat EPZ-6438 UNC0646 Empty
e Empty UNC 0631 C646 RGFP966 JIB-04 MS436 GSK1324726A SRT 1720 (Hydrochloride) EPZ004777 SRT 2104 UNC0638 Empty
f Empty EX-527 Scriptaid EI1 EPZ-5676 UNC1999 BRD9539